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One of the most challenging issues of chemotherapy in cancer treatments relies on 
specifically targeting and carrying the drug to the tumor cells. While tumor ablation 
surgery can be efficient, metastatic cancers are more challenging to treat because of the 
spread distribution of tumor cells in the body. Methotrexate is an FDA approved 
antimetabolite drug for the treatment of breast cancer and acute lymphoblastic leukemia. 
However, despite several conjugation attempts to optimize its delivery to cancer cells, 
methotrexate still does not offer a reliable enough therapeutic effect in the clinic.  
We have investigated the conjugation of methotrexate to annexin A5, a human protein 
that specifically binds to the cancer cell marker phosphatidylserine. Once conjugated to 
annexin A5, methotrexate’s cytostatic effect would be specifically delivered to cancer 
cells without causing off-target damage to healthy cells. This novel drug conjugate has 
been designed as a response to the currently urgent clinical needs for a targeted and 
specific chemotherapeutic treatment for triple negative breast cancer and lymphoblastic 
leukemia.  
The successful conjugation of methotrexate to annexin A5 was confirmed by measuring 
the final concentration of annexin A5 and methotrexate in the conjugate. The increase in 
size of the conjugate was confirmed by SDS-PAGE. Cell viability assays of free and 
conjugated methotrexate were conducted on both tumor and non-tumor cells. The 
conjugate induced a toxicity that was statistically equivalent to the one delivered by the 
free drug on the triple negative breast cancer 4T1 and EMT6 cell lines, and on the 
lymphoblastic leukemia P388 cell line. However, while free methotrexate induces a cell 
mortality in healthy endothelial HUVEC and HAAE-1 cells, the conjugate does not cause 






Cancer disease  
 
Cancer can be defined as a disease based on a group of anarchic cells that circumvent the 
physiological and homeostatic rules of the organism. While every healthy cell is subject 
to a permanent control and regulatory signaling, tumor cells have developed a certain 
independence that allow them to proliferate at an uncontrolled rate. Cancer cells are 
characterized by general hallmarks related to their cellular behavior: sustaining a 
proliferative signal, escaping growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis1–4. By 
sustaining their proliferative signals and evading the growth suppressors, they enable 
themselves to keep a high proliferative rate, provide themselves with the necessary 
growth factors and evade growth suppressors checkpoint of the cell cycle through the 
altered expression of oncogenes5. To further promote its growth, the tumor will 
considerably increase its vasculature by diffusing several angiogenic growth factors such 
as the vascular endothelial growth factor (VEGF) and the fibroblast growth factor (FGF). 
This angiogenesis induction involves the proliferation and migration of endothelial cells 
to the tumor site to supplement the cancer cells with nutrients and oxygen6. Through a 
considerable flexibility of their adhesive properties to other cells and to the extracellular 
matrix (ECM) that allows them to migrate from their initial site, cancer cells are 
transported in the bloodstream and promote secondary tumoral sites that can potentially 




Fig. 1 Tumor evolution to metastasis stage. The primary tumor cells in the epithelial 
tissue proliferate, invade the extracellular matrix, cross the basal membrane, and 
penetrate the blood vessels. Once in the bloodstream, the cells are disseminated 
throughout the body and some cells exit the circulation by extravasation in secondary 
tumor sites, that proliferate into metastasis10.  
 
Breast cancer  
 
Breast cancer is a type of carcinoma, a tumorigenic epithelial tissue. It is the 3rd leading 
cause of death worldwide for females between 50-59 years old11. It can be classified into 
several subtypes according to its hormonal receptor’s expression (estrogen, progesterone 
and HER2 receptors) on the plasma membranes of the tumor cells. Breast cancers that do 
express these receptors are eligible for endocrinal therapy that present a certain specificity 
towards tumor cells. A subtype of breast cancer does not present any of these receptors 
which renders its treatment particularly challenging. Triple negative breast cancer 
(TNBC) accounts for 15% of breast malignancies. If an early stage of the disease can be 
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well addressed by surgery, metastatic and advanced-metastatic tumors are more complex 
to treat. Because of the absence of specific treatment guidelines such as endocrine 
therapy, the TNBC subtype is treated with standard therapies often associated with a high 
rate of local and systemic relapse. The undesirable side-effects observed in 
chemotherapies represent a clinical limit and impair the delivery of the anticancerogenic 
effect of the drugs12. 
Leukemia and lymphoma  
 
Leukemia and lymphoma are the two main types of hematological malignancies. As a 
liquid tumor, cancer cells’ distribution is systemic, and the metastasis occurrence risk is 
high. Lymphoma is exclusively based on lymphoid cell lines, the T and B lymphocytes, 
while leukemia can be based on both lymphoid and myeloid cell lines. Leukemia is 
classified into acute or chronic leukemia according to the maturity of the tumorigenic 
bone marrow cells and is located in the blood circulation. Lymphoma on the other hand, 
affects the lymphatic system through tumorigenic lymphocytes B and T and can be 
divided into Hodgkin (malignant B cells based only) and non-Hodgkin (both B and T 
malignant cells) lymphomas13–18. 
Methotrexate as an anticancer therapeutic 
 
Methotrexate is a chemotherapeutic that has been used in the clinic for over 50 years. It 
is a folate derivative analog that interferes with the de novo synthesis of nucleotides and 
amino acids. Methotrexate is prescribed for the treatment of inflammatory diseases such 
as arthritis, psoriasis, Crohn’s disease but is also an FDA approved chemotherapeutic 
agent for a great number of malignancies such as breast carcinoma, acute lymphoblastic 
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leukemia, non-Hodgkin lymphoma, osteosarcoma, head and neck cancer, and lung 
cancer19.  
With a very similar chemical structure to folic acid, methotrexate consists of a pteridine-
diamine core linked to a glutamic acid moiety that contains two highly ionizable 
carboxylic acids, circled in red in Figure 2. However, its solubility in aqueous solvent is 
pH-dependent and requires neutral or basic pH values20. As a free drug, methotrexate is 
internalized into cells through two types of receptors: RFC, the reduced folate carrier, to 
which it has the highest affinity and the folate receptor FOLR121–24. When methotrexate 
is internalized in the cell, it is converted to methotrexate polyglutamate by the enzyme 
folylpolyglutamate synthetase (FGPS) that adds 
glutamate molecules at the γ-carboxyl moiety of 
methotrexate (Figure 3). If the mono-glutamate 
form of MTX has a high affinity with a number of 
folate export processes, the polyglutamylation of 
methotrexate prevents its efflux and allows for an 
accumulation of the antifolate drug in the cell and 
a sustained inhibition of its targeted enzymes for 
long intervals24. The enzyme dihydrofolate 
reductase (DHFR) is responsible for the reduction 
of folic acid (FA) to tetrahydro folic acid (THF), 
which is the active component necessary for the biosynthesis of thymidylate and purine 
nucleotides. By competitively inhibiting the dihydrofolate reductase enzyme, 
methotrexate leads to a deficiency in the cellular pool of tetrahydrofolate and prevents 
the synthesis of dAMP and dGMP nucleotides. As shown in Figure 3, methotrexate also  
Fig. 2 Chemical structure of 
methotrexate. The two targeted 
carboxylic functions for 
conjugation to annexin A5 are 
circled in red.  
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inhibits thymidylate synthase (TS) that is responsible for thymidine synthesis, one of the 
two necessary pyrimidines for DNA replication and repair. Both decrease of THF and 
inhibition of TS lead to a depletion of thymidylate pool. Moreover, tetrahydrofolate is an  
Fig. 3 Mechanism of action of methotrexate. (1) Methotrexate cellular uptake is 
mediated by the reduced folate carrier (RFC) to which it has the highest affinity and 
the folate receptor 1 (FOLR1) to which folic acid (FA) has the highest affinity; (2) 
Folylpolyglutamate transferase (FGPS) incorporates glutamates on MTX and promotes 
its accumulation in the cell; (3) MTX inhibits dihydrofolate reductase activity (DHFR) 
and decreases the pool of tetrahydrofolate (THF) leading to a decrease of purine 
synthesis and of the repletion of methionine and of the major methyl donor S-
adenosylmethionine (SAM); (4) MTX inhibits the thymidylate synthase enzyme 
responsible for the production of thymidylate (dTMP), an essential component of DNA. 
The figure was drawn using the software © BioRender 2020.   
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essential component for methionine synthesis through the provision of its methyl group 
to homocysteine.  By depleting the available amount of methionine, methotrexate impairs 
the repletion of S-adenosylmethionine which is the universal methyl donor in the cell, 
paramount in nucleic acids expression regulation by methylation. Preventing the repletion 
of the available pool of methionine also limits the overall protein synthesis of cancer cells, 
as methionine is the essential amino acid that initiates the protein synthesis.  Therefore, 
the antimetabolite methotrexate interferes with mitotic cell division, DNA repair and 
RNA and protein synthesis by depriving the cell of its essential nucleotides and amino 
acids biosynthetic pathways25,26. 
The cytotoxic effects of methotrexate occur during the S phase of the cell cycle due to the 
higher dependence of the cells on purine and pyrimidine de novo synthesis making the 
drug mostly active on rapidly multiplying cells. Indeed, malignant tissues display a higher 
proliferation rate and therefore an increased sensitivity to methotrexate action than 
normal tissues. This difference of sensitivity has been for a long time used to consider the 
drug delivery as specific. However, it is known today that free methotrexate 
administrations do not show a satisfactory specificity towards cancer cells and cause 
deleterious side-effects in treated patients. Indeed, tissues and cells that physiologically 
go through a high proliferative rate present a considerable sensitivity to methotrexate: 
bone marrow cell lines, fetal cells, buccal cells, intestinal mucosa or bladder urinary 
cells27. These are consistent with the most related side-effects of methotrexate: bone 
marrow suppression, oral and gastrointestinal ulcers, cutaneous toxicity, but also include 
acute renal failure, neurotoxicity and pulmonary inflammation28.  
However, the lack of specific addressing of MTX limits its therapeutic application in the 
clinic29–31. Several conjugations of MTX have been tested and showed a higher cytotoxic 
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effect when associated with nanoparticles, lysine polymer, albumin, fibrinogen, or lipo-
amino acids. But none of them showed a sufficiently reliable targeted delivery of the drug 
and limited off-targets towards healthy cells27,28,32–56.  
It is known that when administered freely, less than 1% of a given drug will reach the 
tumor site and deliver an anticancer effect; the rest of the fraction is disseminated in the 
organism’s tissues57,58. Methotrexate is easily metabolized by the organism and its fast 
blood clearance limits the tumor exposure to the drug. By combining a chemotherapeutic 
drug to a targeting carrier agent, its distribution to the tumor site can be optimized59, 
which has been observed in albumin conjugates and nanoparticle drug therapeutics35,40–
43,60. Targeted therapies rely on the specific delivery of the chemotherapeutic drug to the 
tumor site, preserving the healthy cells from undesired off-target effects and allowing for 
a lower efficient dose of the drug. Conjugating MTX with a carrier agent specific to tumor 
cells would ensure an optimal and targeted delivery of the molecule to cancer cells 
specifically.   




Phosphatidylserine (PS) is a cancer cell targeting biomarker. It is an essential 
phospholipid ubiquitously present in human cells, expressed in the inner leaflet of the 
plasma membrane. Phosphatidylserine externalization is regulated by the activity of a 
calcium-dependent flippase. This enzyme ensures the rotation of PS towards the 
cytoplasmic side while floppase catalyzes the opposite reaction. The higher the 
intracellular calcium concentration is, the lower the flippase activity gets, promoting the 
externalization of PS on the outer leaflet of the plasma membrane61. PS is externalized in 
apoptotic cells and in a large majority of malignancies.  Phosphatidylserine 
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externalization is a conserved evolutionary immunosuppressive signal that prevents local 
and systemic inflammation. Apoptotic cells externalize PS, circumvent an immune 
activation of lymphocytes and send an “engulf me” signal to macrophages that will bind 
to the ligand PS and proceed to the physiological efferocytosis62–68. Tumor cells utilize 
this immunosuppressive signal by mimicking an apoptotic signal through PS 
externalization and by expressing surface proteins such as CD47 that discourage the 
macrophages from engulfing them69,70. This pacification of phagocytic cells combined 
with the suppression of active immune cells recognition (T-cells and B-cells) is the 
hallmark of the established immunosuppression of tumor cells.  
PS is described as an “underestimated Achille’s heel of cancer” because of the high 
dependence of tumor maintenance in the organism and because of its wide expression in 
cancer pathology. Indeed, PS has been found to be externalized not only in primary cancer 
lesions, but also in metastasis, tumor vasculature, and primary cancer cell lines68,71–73. 
Annexin A5 
 
Annexin A5 (ANXA5) is a member of the membrane binding proteins involved in 
different regulatory functions as a powerful anticoagulant and a cell surface coating agent.  
ANXA5 is an endogenous human protein of around 36 kDa that can bind to PS and 
therefore constitutes a cancer targeted carrier agent. The annexin A5-FITC fluorescent 
conjugate has been commonly used for its applications in flow cytometry and 
fluorescence microscopy for apoptotic cell death assay74–79. ANXA5 binding to PS is Ca2+ 
dependent80,81 and is followed by an internalization in the cell, described as a novel 
macropinocytosis pathway that does not involve any interaction with the actin 
cytoskeleton. ANXA5 is made of a core of α-helices with a Ca2+ binding domain, a PS 
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binding domain, and an ANXA5 binding domain allowing for the formation of trimers. 
Once bound to PS, ANXA5 forms a trimer that binds to another ANXA5 trimer leading  
to a hexamer that forms a two-dimensional lattice. As shown in Figure 4, ANXA5 
ultimately invaginates the plasma membrane followed by the intracellular trafficking of 
the endocytic vesicle71,72,82–88.  
Interest of conjugating methotrexate to annexin A5 
 
The pharmacokinetic properties of methotrexate (fast metabolization and short blood 
clearance) greatly limit the tumor exposure time and the delivered antineoplastic effect.  
This leads to an increase of applied doses in the clinic that usually cause acute side effects 
and chemoresistance mechanisms. By conjugating MTX to ANXA5, the clearance time 
of MTX in blood will be extended, besides acquiring the cancer specific targeting of  
Fig. 4 Binding and internalization of annexin A5. Annexin 
A5 binds to phosphatidylserine (orange) and is internalized in 





annexin A5. The conjugation will rely on EDC-NHS conjugation protocol that allows for 
a zero-length carboxyl to amine cross-linking between the carboxylic acids of 
methotrexate and the primary amines of annexin A5 (Figure 5). This method of 
conjugation has already been successfully utilized in our lab for the development of 
several novel drug conjugates89–91. The methotrexate molecules will be conjugated to 
annexin A5 with amide bonds, providing a high chemical stability to the conjugate and 
preventing an undesired early cleavage of the drug. The annexin A5 triggered endocytosis 
has been reported to involve the lysosome. The acidic pH of the lysosome and the 
powerful enzymatic load contained inside are expected to cleave the conjugate’s amide 
bond and release MTX in the cytosol92 (Figure 6). 
 
 
Fig. 5 Conjugation chemistry of methotrexate (MTX) and annexin A5 (ANXA5) 
using the coupling agent EDC and NHS. This conjugation reaction leads to a stable 






Fig. 6 Binding and internalization of ANXA5-MTX conjugate in cancer cells. The 
drug conjugate binds to externalized phosphatidylserine (yellow) of cancer cells, 
internalizes and releases active methotrexate in the cytosol. The figure was drawn 















We base our work on the combination of two biological properties: the ability of annexin 
A5 to bind to phosphatidylserine and to be internalized in the cell and the cytostatic 
function of methotrexate. Phosphatidylserine being considered as a specific cancer cell 
marker, our hypothesis relies on the preservation of the properties of the two molecules 
once conjugated. The elaboration of a successful conjugate would allow an effective 
binding and endocytosis in the cancer cells and a successful delivery of methotrexate 
antineoplastic effect, with negligible toxicity in healthy cells.  
First objective: Elaboration of a stable annexin A5-methotrexate conjugate  
 
The conjugation chemistry using EDC/NHS coupling is a reliable method to conjugate 
two proteins together and should allow for a good conservation of ANXA5 and MTX 
properties. The conjugates bands on SDS-PAGE are expected to be higher than the one 
of free ANXA5 to confirm the successful conjugation. The final conjugate solution must 
show good solubility and viability of the novel targeted therapeutic.  
Second objective: In vitro assays of the conjugate on tumor and non-tumor cells   
 
The assessment of the novel conjugate therapeutic interest and potential clinical impact 
will be assessed with cell viability assays on tumor and non-tumor cell lines. The 
conjugate toxicity will be tested on breast cancer and leukemia cell lines and compared 
to the one of free MTX. A toxicity at least equivalent or higher is expected from the drug 
conjugate. To test its specificity towards cancer cells, ANXA5-MTX conjugate toxicity 
will also be assessed on healthy endothelial cell lines, and no toxicity is expected.   
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Annexin A5 recombinant production: pET-30 Ek/LIC vector was purchased from EMD 
Chemicals (Billerica, MA). Tryptone, yeast extract, and kanamycin monosulfate were 
obtained from Alfa Aesar (Haverville, MA). Sodium hydroxide, potassium chloride, and 
sodium chloride were from VWR inc (Radnor, PA). Bovine serum albumin (BSA), Triton 
X-100, isopropyl β-D-thiogalactopyranoside (IPTG) and, N-p-tosyl-L-phenylalanine 
chloromethyl ketone (TPCK), phenylmethylsulfonyl fluoride were from Sigma-Aldrich 
(St Louis, MO). HRV-3C protease was from © Thermo Fisher Scientific (Waltham, MA). 
Sodium phosphate was from Mallinckrodt Chemicals (Phillipsburg, NJ). The 14 Da 
dialysis membranes were from Spectrum Laboratories (Rancho Dominguez, CA). His-
trap columns were from GE Healthcare (Chicago, IL). HPLC grade ethanol was from 
Acros Organics (Waltham, MA). HRV-C3 protease was from © Sino Biologics (Wayne, 
PA). Bradford reagent, 1X Laemnli buffer and 4-20% 10-gradient gels were bought from 
BioRad (Hercules, CA).  
Annexin A5-methotrexate conjugate production: Methotrexate was purchased from TCI 
America (Portland, OR). Dimethyl sulfoxide (DMSO) was bought from Sigma-Aldrich 
(St Louis, MO). 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) were purchased form VWR (Radnor, PA).  
Cell culture and in vitro assays: Murine breast cancer cells 4T1 (ATCC® CRL2539™) 
and EMT6 (ATCC® CRL2755™), leukemia cells P388D1 [P388 D1] (ATCC® 
CCL46™), human endothelial HUVEC cells (ATCC® CRL1730™), VCBM, 
Endothelial Cell Growth Kit PCS-100-040, RPMI-1640 medium, Waymouth's MB 752/1 
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Medium, L-glutamine 200 mM, Dulbecco's Modified Eagle's Medium, horse serum, 
Ham’s F-12K medium, and heparin were from ATCC (Manassas, VA). Human 
endothelial HAAE-1 cell line was purchased from Coriel Cell Repositories® (Camden, 
NJ). Fetal bovine serum (FBS) was from Atlanta Biologicals (Lawrenceville, GA). 
Antibiotics penicillin and streptomycin were bought from Invitrogen (Grand Island, NY). 
0.2 µm sterile filtration membranes and TrypanBlue were from VWR (Radnor, PA). 
Alamar Blue reagent was purchased from © Sigma-Aldrich (St Louis, MO).  
Methods 
  
Production of recombinant annexin A5 
 
The pET-30 EK/LIC/ANXA5 plasmid encoding annexin A5 was previously constructed 
in this lab by the PhD student Naveen Palwai93. The bacterial strain E. coli BL21(DE3) 
had been transformed to contain this plasmid and is cultured for the recombinant 
production of ANXA5.  
BL21(DE3) E.coli is first introduced in a preculture of LB medium overnight before to 
be added to the 1 L culture medium containing 35 µg/mL of kanamycin. The bacteria 
cells are cultured at 37°C with a 200 rpm shaking. The OD of the culture medium is 
regularly monitored with a spectrophotometer at 600 nm, as an indicator of the bacterial 
growth. Once an optical density of 1.2 is reached, the culture media is induced by the 
addition of 238 mg of isopropyl β-D-thiogalactopyranoside (IPTG) to induce the 
constitutive expression of ANXA5. The induction step lasts 19 hours, and the cells are 
cultured at 25°C to lower the overall protein expression and promote the major production 
of ANXA5. The next step of the production is to centrifuge the cell culture at 4000 g for 
15 minutes to collect the bacterial cells and remove the media. The pellet containing the 
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cells is then resuspended in a sonication buffer, and the suspension is sonicated 30 
seconds at 4.5 W. This sonication is repeated four times for a total sonication time of 2.5 
minutes on power level 4. The sonication step aims at breaking the cells membranes to 
release the produced ANXA5 from the cytosol. A centrifugation step at 12 000 g for 10 
minutes is then necessary to separate the soluble proteins fraction from the cell debris and 
other insoluble components. The supernatant containing the proteins is then retrieved and 
is purified using a Ni2+ chromatography His-trap column. The ANXA5 is produced in the 
E. coli cells with a His-TAG that have an affinity with the Ni2+ ions of the column. With 
the use of the appropriate washing buffer and elution buffers, the protein fraction obtained 
from the centrifugation is eluted in the column in order to trap the ANXA5-His-TAG in 
the column and eliminate the undesired non tagged proteins. The elution buffer containing 
a high concentration of imidazole will release the trapped ANXA5-His-TAG from the 
column. ANXA5 is then collected and cleaved overnight by adding 10 U of HRV-3C 
protease per mg of ANXA5. The protease will cleave the C-terminal His-TAG of the 
protein. The protease also has a C-terminal His-TAG. Thus, the cleaved ANXA5 will be 
eluted again in the Ni2+ chromatography column that will trap the protease and release the 
cleaved protein. The obtained ANXA5 solution is then dialyzed against 2 L of phosphate 
buffer saline (PBS) to remove the remaining Imidazole and detergent Triton-X present in 
the washing and elution buffer. An SDS-PAGE will confirm the successful production 
and purification of ANXA5 by observing a single band between 36 and 37 kDa. If not 
used in the next 12 hours, the ANXA5 will be flash frozen in liquid nitrogen and stored 
at -80°C.  
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Elaboration of the novel methotrexate conjugation to annexin A5   
 
Methotrexate has several aromatic cycles in its chemical structure and is photosensitive. 
To preserve its biological properties and its absorbance abilities, all the following 
experiments containing methotrexate included a protection from light with foil. The 
preparation of the ANXA5-MTX conjugate was first designed like the one of 
chlorambucil conjugation to annexin A5, as the chemistry of the conjugate was very 
similar90,91. The first step is the esterification of methotrexate carboxylic functions with 
EDC to form the unstable O-acylisourea. This intermediate is very reactive towards amine 
functions to form amide covalent bonds but is also sensitive to hydrolysis. To do so, 3 mg 
of methotrexate, for instance, are dissolved in 3 mL of PBS. A 10-molar excess of EDC 
is added, and the solution is vortexed for 5 minutes and strongly stirred for 15 minutes. 
Then, a 7-molar excess of sulfo-NHS is added to increase the solubility of methotrexate 
ester and to limit the hydrolysis of MTX ester by pushing the reaction sense towards the 
formation of the amide bond. EDC being reactive with all carboxylic acids, to limit the 
formation of undesired cross-linked proteins, 2 µL of β-mercaptoethanol are added to 
quench the excess of EDC. The methotrexate sulfo-NHS ester solution is then titrated to 
a pH of 7.4 before being added dropwise to the annexin A5 PBS solution. The protein 
solution is gently stirred while adding the drug to promote the solubilization and reaction. 
After 12 hours of gentle stirring at 4°C, the ANXA5-MTX solution is centrifuged at 
12 000 g for 10 minutes to remove the unconjugated MTX, precipitated ANXA5, and the 
other undesired chemicals (EDC, NHS, β-mercaptoethanol). Finally, the conjugate 
undergoes an overnight dialysis against 2 L of PBS at pH 7.4 to remove the unconjugated 
methotrexate still soluble.  
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Characterization of the novel annexin A5-methotrexate conjugate  
 
Absorbance spectroscopy for concentration determination 
 
The first step in characterizing the ANXA5-MTX conjugate is determining both annexin 
A5 and methotrexate concentrations. The repeated dialysis steps at the end of the 
conjugation ensure that the remaining methotrexate molecules are conjugated and the 
ratio of the two concentrations will give the loading ratio of MTX per ANXA5.   
As the pterin moiety of methotrexate strongly absorbs in the UV-visible spectrum through 
its heteroaromatic chromophore cycle, the absorbance peak of methotrexate at 370 nm 
will be used to establish an absorbance standard curve20. The absorbance peak at 370 nm 
was preferred over the ones at 254 nm and 300 nm because it overlaps the least with 
protein absorbance at 280 nm. A minimum mass of 2 mg of methotrexate, to limit the 
uncertainty of the scale, is dissolved in PBS. The primary solution will undergo serial 
dilutions to obtain the desired range of concentrations of the drug (10 to 180 µM). The 
absorbance of the different samples will be measured at 370 nm in triplicate with a 
spectrophotometer to obtain a linear correlation between methotrexate concentration and 
absorbance. For the establishment of the standard curve, only the concentrations giving 
an optical density less than 1 will be considered, ensuring the linearity of the curve.  
The annexin A5 concentration dosing is assayed with the Bradford protein assay. When 
exposed to proteins, the Bradford reagent acquires a blue color, and its absorbance at 590 
nm is proportional to the protein concentration. The Bradford protein assay being a 
standardized assay for all proteins, bovine serum albumin is used to establish a standard 
curve of absorbance for proteins, applicable to measure annexin A5 concentration.  
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The contributions of the absorbance of MTX to the Bradford assay at 595 nm and the one 
of annexin A5 at 370 nm were checked.  
SDS-PAGE analysis 
 
Once both annexin A5 and methotrexate concentrations were calculated and the loading 
ratio of the drug conjugate determined, the successful conjugation of the antimetabolite 
drug to annexin A5 was confirmed by SDS-PAGE. The samples are mixed with 50% 1X 
Laemnli running buffer with 5% β-mercaptoethanol to break the disulfide bounds and 
heated in boiling water to get the proteins in their linear form to standardize their 
migration. The samples are then loaded in a 4-20% 10-gradient gel, migrate in a Tris-
glycine-SDS running buffer under 170 V for 30 minutes, stained with Imperial stain, and 
washed with DI water. Despite denaturing the migrating proteins samples due to the 
presence of sodium dodecyl sulfate and β-mercaptoethanol, the expected covalent amide 
bond between MTX and ANXA5 will be preserved. The conjugate should display a 
higher molecular weight than the free ANXA5, which will be confirmed by a higher band 
of the free ANXA5 than the ANXA5-MTX conjugate on the gel. Moreover, the SDS-
PAGE results will also indicate the purity of the conjugate. Since ANXA5 has both 
primary amine and carboxylic acid functions in its structure, the EDC mediated 
conjugation can lead to the formation of ANXA5 cross-linked by-products, which are 
undesired because their binding to PS could be altered. The analysis of the ANXA5-MTX 
conjugate allows for an estimate of the extent of this cross-linked species and for the 
general protein purity in the final conjugate solution.  
pH kinetic release assay 
 
The stability and kinetic profile of the drug conjugate was studied in physiological 
conditions. While the covalent amide bond is strong and stable, it is known that pH and 
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temperature can influence its chemical stability and possibly lead to a cleavage of the 
conjugate and a release of methotrexate. The specificity of the therapeutic conjugate relies 
on the stability of this bond. ANXA5-MTX conjugate (3.2 mg in 2 mL) containing 150 
µM of MTX was put in a MWC0 14 000 Da dialysis bag in 50 mL of dialysis buffer at 
37°C under mild agitation. The concentration of MTX in the buffer was periodically 
measured spectrophotometrically, by withdrawing 5 mL of buffer at predetermined time 
intervals and replenishing the samples with an equal volume of fresh medium. This 
provides a curve of cumulated released MTX concentration through time. The assay was 
conducted in two different pH buffers: the physiological extracellular pH of 7.4 and the 
tumor extracellular pH of 6.6. A positive control was used with a dialysis bag containing 
free MTX at the same concentration as the ANXA5-MTX conjugate. 
Storage conditions stability assay 
 
Because of the possible effect of extended times in extreme temperatures on protein 
viability, storage of the ANXA5-MTX conjugate may have an impact on the stability and 
conservation of the therapeutic agent. To assay the storage conditions of the conjugate, 
samples stored for different times at -80°C and 4°C were characterized and compared to 
their initial values of ANXA5 and MTX concentrations. The samples are dialyzed for 2 
hours against 2 L of PBS to remove the unconjugated methotrexate and centrifuged at 
3000 g for 5 minutes to remove the precipitated and insoluble annexin A5 proteins.    
Cell culture conditions 
For all described murine and human cell lines, the cells were cultured in an incubator at 
37°C with 5% CO2 in T-75 flasks. The sub-cultures were continuously passaged when a 
confluency of 70% was reached to maintain the cell populations in an exponential phase. 
The cryopreservation was ensured by adding 5% of DMSO and putting the cells overnight 
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in isopropanol before storing them at -80°C in the cryotank. All treatment samples were 
sterile filtered using 0.2 µm membranes before being administered to cells.  
Cell counting  
 
The adherent cell culture to count is trypsinised with 2 mL of trypsin-EDTA for 5 minutes 
at 37°C. Culture medium (8 mL) is added and the cell suspension is centrifuged at 500 g 
for 5 minutes to remove the trypsin. The supernatant is discarded, and the pellet is 
resuspended with 10 mL of medium. Then 100 µL of the final suspension is retrieved and 
counted with a hemocytometer using TrypanBlue exclusion cell viability reagent. For the 
non-adherent P388 cell culture, the cell counting was performed by directly collecting 
100 µL from the cell culture flask.  
Breast cancer cell lines 
 
Two metastatic triple negative breast cancer murine cell lines were used. Both are highly 
tumorigenic and invasive. 4T1 (ATCC® CRL2539™) is a mammary gland carcinoma 
cell line that is an animal model for stage IV of human breast cancer. It is cultured in 
RPMI-1640 supplemented with 10% of FBS and 1% of Anti-Anti 
(antimycotic/penicillin/100 U.mL-1).  
EMT6 (ATCC® CRL2755™) is a mammary carcinoma cell line and is cultured in 
Waymouth's MB 752/1 medium supplemented with 15% of FBS, 2 mM of L-glutamine 
and 1% of Anti-Anti.  
Leukemia cell line  
 
P388 D1(ATCC® CCL46™) is a murine lymphoblastic leukemia non-adherent cell line. 
P388 cells are malignant monocytes grown in suspension that differentiate into adherent 
macrophages. They are grown in DMEM medium supplemented with 10% horse serum 
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and 1% of Anti-Anti. To maintain the cell culture in an exponential phase, the P388 
culture was regularly counted and maintained to a concentration of 2 – 5.105 cells/mL.   
Healthy endothelial cell lines 
 
Two human non-tumorigenic endothelial cell lines were chosen to assay the cancer cells 
specificity of the ANXA5-MTX conjugate. As the therapeutic agent will be considerably 
exposed to the endothelium of blood vessels during its transport in the blood stream, the 
toxicity of the novel drug conjugate on endothelial cells will provide a relevant estimation 
of its off-target potential and specificity towards tumor cells.  
HUVEC (ATCC® CRL1730™) is a cell line based on human umbilical vein 
endothelium. It is cultured with VCBM medium supplemented with the Endothelial Cell 
Growth Kit PCS-100-040 containing 10 mL of FBS, 1% Anti-Anti, 25 mL L-glutamine, 
0.5 mL ascorbic acid, 0.5 mL heparin sulfate, 1 mL of bovine brain extract, 0.5 mL of 
rhEGF, and 0.5 mL of hydrocortisone.  
HAAE-1 (Coriel Cell Repositories®) is a cell line from the human abdominal aorta 
endothelium. This cell line is cultured with the Ham’s F-12K medium supplemented with 
0.1 mg mL−1 heparin, 0.03 mg mL−1 endothelial cell growth supplement, 10% fetal bovine 
serum, and 1% of Anti-Anti.  
Alamar Blue cytotoxicity in vitro assay 
 
The Alamar Blue® cell viability reagent is a cytotoxicity assay relying on the reduction 
of the poorly fluorescent blue indicator dye resazurin into the pink highly fluorescent 
resorufin94. The Alamar Blue test was chosen because more convenient to realize: the 
reagents have a good solubility in water, and no steps of dissolution or resuspension are 
needed, therefore reducing the variability of the volumes of the wells before the reading 
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step. The reduction of resazurin is performed by the mitochondrial electron transport 
enzymes, considered here as a life indicator. By measuring the fluorescence at an 
excitation wavelength of 530 nm and an emission wavelength of 590 nm, the cell viability 
can be quantified and standardized with a control condition. The Alamar Blue assays was 
conducted on 96-well plates with a cell seeding and incubation times that depend on the 
cell line (detailed protocol is provided in the appendix). When treated, the cells receive 
fresh media containing 2 mM of Ca2+ and different concentrations of treatment (free MTX 
and ANXA5-MTX). At the end of the treatment time, the media of the plate was replaced 
with fresh new media containing 10% of Alamar reagent. A triplicate of unseeded wells 
only containing culture medium was used to remove the noise of the overall fluorescence. 
Several triplicates of untreated wells will serve as positive control for the 100% cell 
viability. To limit the variability of the wells volumes due to evaporation in the incubator, 
the outer wells of the plates were not used and instead filled with 200 µL of PBS. The 
treated wells fluorescence was divided by the positive control one to give a percentage of 
cell viability. The IC50 values (inhibitory concentration at 50% viability), that is the main 
cytotoxicity indicator for a drug, was calculated with the IC50 calculator of the website 
AAT Bioquest. 
Statistical Analysis  
 
Cytotoxicity analysis of IC50 data in tumor cells assays was performed using a Student 
t-test, and a one-way ANOVA with a Tukey-Kramer multiple comparisons test was 
performed to analyze the non-tumor cells viability assays using R Studio 2020 software. 





Protocol development for the novel conjugation of methotrexate to annexin A5 
 
Despite of the solubility of around 1 mg/mL of MTX in PBS, the formation of the O-
acylisourea intermediate by esterification of MTX carboxylic acid with EDC imide bond 
considerably decreased the solubility of the drug in PBS and limited the conjugation to 
ANXA5 due to high precipitation and loss of MTX. The adding of sulfo-NHS, which is 
supposed to enhance the solubility of MTX, did not have any effect. The first step of 
protocol optimization was to dissolve MTX and EDC in DMSO, in which the drug 
solubility is higher (3 mg/mL). MTX has a higher solubility in DMF (14 mg/mL), but the 
use of this solvent requires an extra step of decantation due to the formation of urea 
precipitates39. To enhance the linking of MTX to EDC, a 15 minute-water bath at 50°C 
was found to be efficient40–42. As DMSO can cause an alteration of proteins at high 
concentrations leading to crystallization, precipitation, and denaturation, it was made sure 
that the DMSO fraction would not exceed 10% of the total reaction volume95. Not adding 
the quencher β-mercaptoethanol was found to contribute to the successful binding of 
MTX to ANXA5, suggesting that the conjugation reaction would still occur during the 
dialysis step. Also, it was found that slowly adding the esterified MTX to the ANXA5 
solution in PBS dropwise while regularly stirring the vial made the solution clearer and 
less turbid, and highly increased the ANXA5 and MTX yield by limiting their 
precipitation. The pH of the solution was carefully adjusted to 7.4 ± 0.02 while adding 
the DMSO solution of MTX and EDC to preserve the biological function of ANXA5. 
The reaction time between ANXA5 and MTX was shortened from 12 hours to 30 minutes 
and switched to room temperature instead of 4°C to optimize the kinetics of the reaction. 
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To maximize the contact time between ANXA5 and MTX, it was chosen to centrifuge 
the conjugate solution only after dialysis and not before. The centrifuge parameters were 
also optimized to be lowered to 3000 g for 5 minutes to remove the precipitated ANXA5 
and cross-linked chemicals that were not removed during dialysis, while preserving a 
maximum of soluble conjugates in the clear supernatant. The final optimized novel 
protocol of conjugation of methotrexate to annexin A5 is available in the appendix.  
Establishment of methotrexate absorbance standard curve 
 
Fig. 7 Standard curve of methotrexate abosrbance at 370 nm in PBS. The data 
points were obtained from triplicate absorbance values of samples from 10 to 185 µM 
of MTX using a spectrophotometer.                        .      
 
Methotrexate has the characteristic to have an absorbance peak at 370 nm. This physical 
property of the molecule is used to establish the standard curve that will allow for an easy 
and reliable way of measuring its concentration in a solution. The absorbance at 370 nm 
has been measured over a range of concentrations of MTX in triplicate in PBS from 10 
to 185 µM (Figure 7).  



















[MTX] in µM 
Methotrexate absorbance standard curve at 370 nm 
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Gel electrophoresis image of the ANXA5-MTX conjugate 
 
Figure 8 shows the SDS-PAGE gel migration of the free annexin A5 and the conjugated 
protein to methotrexate. From this gel, we can see that the conjugate has a slightly higher 
molecular weight than the free protein, confirming the successful EDC/NHS mediated 
conjugation, that led to the formation of a stable amide bond between the carboxylic 
functions of methotrexate and the amine functions of annexin A5. To get the exact loading 
ratio of the conjugate, the MTX concentration of the final conjugate solution is measured 
with the standard curve and the number of MTX per ANXA5 is deduced. Repeated steps 
of dialysis at the end of the conjugation allows for the complete removal of unconjugated 
methotrexate and ensures that the drug concentration dosed is the conjugated one. It is 
recommended by Thermo Fisher to couple the reaction of esterification with sulfo-NHS 
to promote the reaction sense to the formation of the stable amide bond of the final 
conjugate and limit the hydrolysis of the MTX-EDC intermediate component. The 
loading ratio, number of conjugated MTX molecules per annexin A5, was calculated by 
determining the ratio of each concentration. As observable in Figure 8, the conjugate in 
the lane 3 with a loading ratio of 4 with the single EDC coupling method is slightly 
smaller than the conjugate based on EDC-NHS coupling method with a higher loading 
ratio of 7. However, if sulfo-NHS does increase the loading ratio of the ANXA5-MTX 
conjugate, it also causes a higher formation of cross-linked proteins and a more smeared 
band on the SDS-PAGE, reflecting a higher heterogeneity of the number of MTX per 
annexin A5 in the final conjugate solution. Therefore, it has been chosen to carry the 
following conjugation strategies only with the EDC coupling that offers a lower loading 


















Fig. 8 SDS-PAGE of free ANXA5 and ANXA5-MTX conjugates. Molecular ladder 
(1) ; Purified and cleaved annexin A5 (lanes 2, 4, 6); Annexin A5-methotrexate conjugate 
based on EDC coupling with a loading ratio of 4 (lane 3); Annexin A5-methotrexate 
conjugate based on EDC-NHS coupling with a ratio of 7 (lane 5).  
 
Release Kinetic assays of the ANXA5-MTX conjugate 
 
Figure 9 shows the cumulative release of methotrexate from ANXA5-MTX conjugate in 
PBS at 37°C, at pH 7.4 and 6.6. A free MTX sample was added to the experiment as a 
positive control. All three samples had the same concentration of drug at the beginning 
of the assay (150 µM). We can see that almost the totality of free MTX was released in 
approximately 3.5 hours, while the conjugated methotrexate released around 30% of its 
methotrexate total amount in 48 hours, for both pH values of 7.4 and 6.6. These release 
kinetic assays confirm that the amide bond between MTX and annexin A5 obtained from 





















the EDC/NHS conjugation is not lysed by a 48-hour exposure to physiological conditions 
(37°C, pH of 7.4). Moreover, this assay also shows that the acidic tumoral environment 
(pH of 6.6) does not induce an early cleavage of the conjugate, supporting the hypothesis 
that conjugated methotrexate will be internalized in the cancer cells through annexin A5 
binding pathway to phosphatidylserine. It also reinforces the specificity of ANXA5-MTX 
conjugate towards cancer cells by showing a low release of the drug in the extracellular 
media, that could potentially damage healthy cells.  
  
Fig. 9 Release kinetic assay of free MTX and ANXA5-MTX conjugate. Cumulative 
release of MTX in free MTX (blue), ANXA5-MTX conjugate at pH 7.4 (orange) and 
ANXA5-MTX conjugate at pH 6.6 (grey), in PBS at 37°C. Data points were obtained 
from triplicate absorbance values at 370 nm using a spectrophotometer.  
 
Storage stability assay of ANXA5-MTX conjugate  
 
To evaluate the impact of the storage conditions at 4°C and -80°C on the ANXA5-MTX 
conjugates, the final concentrations of annexin A5 and methotrexate are measured and 
the percentages from the initial concentrations are deduced and used as an indicator of 




























Release kinetic assay of MTX in PBS at 37°C
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potentially unconjugated methotrexate. The samples are then centrifuged at 3000 g for 5 
minutes to discard all precipitated annexin A5.  
Stability assay of ANXA5-MTX conjugate at 4°C (fridge) 
 
Table. 1 Table of percentages of final concentration of annexin A5 and methotrexate in 
conjugates, stored for different times at 4°C. Measurements were done on five different 
conjugates after 2 hours of dialysis in PBS and 5 minutes of centrifugation at 3000 g.  
 
Stability assay of ANXA5-MTX conjugate at -80°C (freezer) 
 
Table. 2 Table of percentages of final concentrations of annexin A5 and methotrexate in 
conjugates, flash frozen in liquid nitrogen and stored for different times at -80°C. 
Measurements were done on five different conjugates after 2 hours of dialysis in PBS and 
5 minutes of centrifugation at 3000 g.  
 
Results of Table 1 show that samples stored at 4°C have a satisfactory annexin A5 
conservation up to the first 6 weeks of storage (80.56% of preserved annexin A5 after 46 
days at 4°C). However, the number of viable proteins decreases considerably after 3 
months (31.4% after 63 days) and is undetectable on a Bradford assay after 4 months. 
ANXA5-MTX Conjugate Time of storage (4° C) % of initial 
[ANXA5] 
% of initial 
[MTX] 
A 4     days  90.5 % 82.5 % 
B 46   days 80.6 % 46.0 % 
C 55   days  59.9 % 55.2 % 
D 63   days  31.4 % 52.4 % 
E 4 months  00.0 % 33.3 % 
ANXA5-MTX Conjugate  Time of storage (-80° C) % of initial 
[ANXA5]  
% of initial 
[MTX]  
F 38   days 98.7 % 89.8 % 
G 55   days  98.3 % 65.4 % 
H 116 days  82.4 % 41.5 % 
I 116 days  96.1 % 72.5 % 
J 4 months   99.2 % 61.5 % 
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The decrease in methotrexate concentration through time is attributable to both annexin 
A5 carrier loss and amide bond cleavage. The storage assays result at -80°C (Table 2) 
show a significantly better conservation of annexin A5 when flash frozen in liquid 
nitrogen (99.2% of initial annexin A5 amount is preserved after 4 months of storage at -
80°C). However, the cryopreservation still induces a certain loss of conjugated 
methotrexate: 41.54% of initial conjugated drug concentration was measured after 116 
days of storage and 61.5% of another conjugate after 4 months. Given the high 
conservation of ANXA5, the loss of conjugated MTX is mostly due to a cleavage of the 
amide bond of the drug conjugate induced by the temperature changes.  
Cytotoxicity assays results 
 
The therapeutic impact of the novel ANXA5-MTX conjugate relies on two main 
conditions. The drug conjugate must first be able to deliver an antineoplastic effect that 
is at least as efficient as the one delivered by the free drug on cancer cells. Also, the 
conjugate must display a certain specificity towards cancer cells and is expected to deliver 
a non-significant toxicity when exposed to healthy cells that do not externalize 
phosphatidylserine. To analyze and compare the toxicities of the treatments on cancer 
cells, the parameter IC50 will be calculated and exploited. In this case, the IC50 is the 
concentration of drug necessary to induce 50% of cell death, meaning that a lower IC50 
indicates a higher potency of the drug. The following in vitro assays present the cell 
viability results on two healthy human endothelial cell lines and three murine tumor cell 
lines when treated with free and conjugated MTX.  
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Non-tumor cell viability assays 
 
HAAE-1 cell line 
 
Figure 10 shows the toxicity of the free and conjugated methotrexate on healthy human 
HAAE-1 endothelial cells, that are extracted from the abdominal aorta. We can see that 
the ANXA5-MTX conjugate does not cause a significant cell mortality, whereas the free 
MTX induces a cell mortality that goes up to 45% at 30 µM. The HAAE-1 cell line has 
already been used as a healthy model of cells96, that do not externalize the 
phosphatidylserine when a confluency close to 100% is reached. Methotrexate is a 
chemotherapeutic that is mostly active on cells in phase S; the high confluency of the 
cells during the Alamar Blue assay explains why methotrexate cell toxicity is lower than 
in the tumor cell lines. These results support the specificity of the ANXA5-MTX 
conjugate towards cancer cells via phosphatidylserine binding.  
Fig. 10 Alamar Blue assay on human healthy endothelial HAAE-1 cells after 48 hours 
of treatment. Free methotrexate (orange) and ANXA5-MTX conjugate with a drug ratio 
of 6 (blue). The cells were seeded at 10,000 per well with 200 µL of Ham’s F-12K media, 
each, then treated 48 hours after when a confluency of 90% was reached. Data is presented 
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HUVEC cell line  
 
To strengthen the last results on the HAAE-1 cell line, a similar cell viability assay was 
conducted on the HUVEC cell line. HUVECs are non-tumor cells cultured from human 
umbilical vein endothelium. Like HAAE-1, they are known to not externalize the 
phosphatidylserine when a confluency close to 100% is reached. The results of the cell 
viability assay clearly indicate that while free MTX induces a cell mortality that reaches 
51% with a 44 µM drug concentration, the conjugate does not induce a statistically 
significant cell mortality at equivalent concentrations (Figure 11). These results are 
consistent with the HAAE-1 cell results and confirm that the ANXA5-MTX conjugate 
does not induce a significant cell mortality on healthy endothelial cells.   
as mean ± SE (n = 3). Statistical significance of conjugate versus MTX denoted by * (P < 
0.05).  
 
Fig. 11 Alamar Blue assay on human healthy endothelial HUVECs cells after 48 
hours of treatment. Free methotrexate (orange) and ANXA5-MTX conjugate with a 
drug ratio of 6 (blue). The cells were seeded at 10,000 per well with 200 µL of VCBM 
media, each, then treated 48 hours after when a confluency of 90% was reached. Data 
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Tumor cells viability assay 
 
MTX is an FDA approved chemotherapeutic drug for a wide range of malignancies 
including breast carcinoma, acute lymphoblastic leukemia, and non-Hodgkin lymphoma. 
Proving that the toxicity of ANXA5-MTX conjugate is at least equivalent to the one of 
the free MTX would establish the therapeutic impact of the novel drug conjugate on 
already FDA approved malignancies. The following in vitro results present the cell 
viability assays of one non-adherent P388 cell line and two adherent 4T1 and EMT6 
tumor cells.  
P388 cell line  
 
The P388 cell line consists of tumorigenic monocytes and macrophages that are 
commonly used as a model for leukemia and lymphoma studies97–101. In Figure 12, we 
can see that the two cell viability curves are close, indicating that the free MTX and 
ANXA5-MTX conjugate have comparable toxicities to P388 cells.  The experiment was 
repeated two more times, and a Student test was conducted on the two groups of three 
IC50s of the three experiments.  The resulting calculated mean IC50 are respectively 0.21 
± 0.12 µM for free MTX and 0.11 ± 0.01 µM for ANXA5-MTX. A P value of 0.34 was 
obtained, confirming that ANXA5-MTX conjugate has a toxicity towards the leukemia 
and lymphoma cell model that is statistically equivalent to the one delivered by the free 
drug. These results are encouraging and show a therapeutic potential in improving 
methotrexate clinical treatment in acute lymphoblastic leukemia and non-Hodgkin 
lymphoma. 
is presented as mean ± SE (n = 3). Statistical significance of conjugate versus MTX 
denoted by * (P < 0.05). 
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Fig. 12 Alamar Blue assay on murine leukemia P388 cells after 48 hours of 
treatment. Free methotrexate (orange) and ANXA5-MTX conjugate with a drug ratio of 
6 (blue). The cells were seeded at 20,000 per well with 200 µL of DMEM media. Data is 
presented as mean ± SE (n = 3). 
 
EMT6 cell line  
 
EMT6 cell line has recently emerged as a valuable pre-clinical model of study for triple 
negative breast cancer102–108. In Figure 13, we can see the proximity of the sigmoid cell 
viability curves of free and conjugated MTX. The experiment was repeated two more 
times, and a Student test was conducted on the two groups of three IC50s of the three 
experiments.  The resulting calculated mean IC50 are respectively 0.03 ± 0.00 µM for 
free MTX and 0.18 ± 0.06 µM for ANXA5-MTX. A P value of 0.18 was obtained. The 
ANXA5-MTX conjugate delivers a toxicity on EMT6 triple negative breast cancer cells 


























Leukemia cancer P388 cell line - Alamar Blue assay 
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Fig. 13 Alamar Blue assay on murine breast cancer EMT6 cells after 48 hours of 
treatment. Free methotrexate (orange) and ANXA5-MTX conjugate with a drug ratio 
of 6 (blue). The cells were seeded at 5000 per well with 200 µL of Waymouth medium.  
Data is presented as mean ± SE (n = 3). 
 
4T1 cell line  
 
4T1 cells are a murine model for stage IV of human triple negative mammary gland 
carcinoma. In Figure 14, we can see again the proximity of the cell viability curves of 
free MTX and ANXA5-MTX. The experiment was repeated two times and a Student test 
was conducted on the two groups of three IC50s of the three experiments. The resulting 
calculated mean IC50 are respectively 0.1 ± 0.00 µM for free MTX and 0.38 ± 0.11 µM 
for ANXA5-MTX. A P value of 0.174 was obtained, confirming the equivalent toxicity 
of ANXA5-MTX conjugate to free MTX on 4T1 cells.  
Despite of not having obtained a drug conjugate with an increased toxicity on cancer cells 
compared to the free drug, ANXA5-MTX has induced a toxicity statistically comparable 
































breast cancer 4T1 and EMT6 cells. This conclusion shows that the EDC/NHS conjugation 
chemistry to ANXA5 did not significantly impact MTX antineoplastic function. 
Significantly, ANXA5-MTX did not deliver a significant cytostatic effect in the two 
healthy endothelial cell lines tested in this work, confirming the effective targeting of 
ANXA5 towards phosphatidylserine and the preservation of ANXA5 biological function. 
The combination of these two conclusions strongly support the therapeutical potential of 
the novel ANXA5-MTX conjugate to respond to the urgent needs of improving 




Fig. 14 Alamar Blue assay on 4T1 breast cancer murine cell line after 48 hours of 
treatment. Free methotrexate (orange) and ANXA5-MTX conjugate with a drug ratio 
of 6 (blue). The cells were seeded at 5000 per well with 200 µL of RPMI-1640 medium.  
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Cancer is one of the most challenging diseases to treat nowadays. The difficulty to find a 
successful treatment comes from many properties of the tumor cells. Their ability to 
develop chemoresistance, to promote anarchic angiogenesis in their microenvironment, 
and metastasis to ectopic sites renders most of current treatments partially or poorly 
efficient. Leukemia and lymphoma are liquid tumors for which recommended treatments 
can be chemotherapy, radiation therapy, or bone marrow transplant. Triple negative breast 
cancer is a type of malignancy that does not express any receptor sensitive to hormonal 
therapy (estrogen receptors, progesterone receptors or HER2) and which the easiest way 
to treat is the surgical ablation of the tumor. However, if these malignancies develop 
metastasis, surgery is no longer efficient as a treatment. Methotrexate is a well-known 
chemotherapeutic agent approved for the treatment of many malignancies. However, its 
fast metabolization in the organism considerably limits its efficient delivery to the tumor 
site. It is known that less than 1% is estimated to reach the tumor site, the rest of the drug 
fraction being randomly distributed in the body.  
The current increase of MTX necessary doses to observe a tumor decline in the clinic are 
also responsible for many deleterious clinical side effects. Targeted therapies against 
cancer therefore play a central role in the development of optimum novel anti-tumor 
treatments. They allow for a higher delivered drug fraction to the tumor site without 
damaging the non-tumor cells, which lowers the administered doses in patients and limits 
the development of chemoresistance from the tumor. As presented here, we propose to 
exploit the property of the protein ANXA5 to bind to phosphatidylserine. 
Phosphatidylserine is a phospholipid ubiquitously present in eucaryotic cells but is mainly 
externalized in apoptotic and tumor cells.  
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By conjugating the chemotherapeutic agent MTX to ANXA5, we design a novel targeted 
treatment that presents a high therapeutic potential regarding the current clinical needs of 
chemotherapy. ANXA5-MTX was successfully produced using the standard EDC/NHS 
coupling and after optimizing different steps of the pre-established conjugation protocol 
used for chlorambucil conjugation. The novel conjugate was obtained with satisfactory 
ratios going from 2 to 19 molecules of MTX per ANXA5, confirmed by the higher 
conjugate bands than the free protein band on the SDS-PAGE. The cytotoxicity assays 
did not show a higher toxicity of the conjugate compared to the free drug as with the 
chlorambucil or DM1 conjugate previously elaborated90,91. However, ANXA5-MTX was 
found to have a toxicity statistically equivalent to free MTX on lymphoma P388 cell line 
and triple negative breast cancer 4T1 and EMT6 cell lines. This proves that the conjugated 
formulation does not significantly impact MTX cytostatic function.  
One of the most probable reasons for not observing a higher toxicity of the conjugate is 
that methotrexate internalization in the cells is mediated by active ATP-dependent 
transport via the reduced folate receptor FOLR1 and the folate receptor RFC21–24. Indeed, 
as a folate analog, free MTX is recognized by the cells and undergo an active endocytosis 
that compete with the ANXA5 internalization through phosphatidylserine. Furthermore, 
we know that ANXA5 internalization is complex and depends on several factors. The 
calcium-dependent endocytosis goes through the formation of a trimer of bonded ANXA5 
to phosphatidylserine that then assembles to another trimer to form a two-dimensional 
lattice that will then induce a macropinocytotic endocytosis in the cancer cell. Moreover, 
the conjugate did not induce any significant cell death on the two tested healthy 
endothelial cell lines HAAE-1 and HUVEC, highlighting the therapeutic promising 
potential of the innovative ANXA5-MTX drug conjugate. These assays on healthy cells 
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prove that the conjugated methotrexate toxicity delivery is mediated by ANXA5 binding 
to phosphatidylserine, and that the conjugation design prevents the drug to exert its 
cytostatic function when exposed to healthy cells. However, it is important to confirm the 
behavior of ANXA5-MTX conjugate on non-endothelial healthy cells such as mammary 
epithelial cells and healthy monocytes and lymphocytes to strengthen the specificity of 
the conjugate. Moreover, in vivo assays using mice would give further information on the 
pharmacokinetics of the conjugated MTX compared to the free one in a living organism. 
Indeed, several non-targeted MTX designed conjugates such as albumin or nanoparticles 
showed promising in vivo results because of the lowered blood clearance of the 
conjugated MTX, its resistance to being metabolized, and the better exposure to the tumor 





















One of the most currently challenging issues of chemotherapy in cancer treatments relies 
on specifically targeting and carrying the drug to the tumor cells. Annexin A5 presents a 
high potential regarding this challenge as it can specifically bind to phosphatidylserine 
and be internalized in the cell. Because phosphatidylserine is externalized only in 
apoptotic and tumor cells, annexin A5 is a promising candidate for conjugation as a drug 
carrier. Methotrexate is a folate analog that inhibits the synthesis of nucleotides necessary 
for DNA replication and protein synthesis. Methotrexate is approved for the treatment of 
many malignancies, but there is an urgent clinical need for the development of a targeted 
chemotherapy as the available therapies including methotrexate induce considerable side 
effects and chemoresistance in the treated patients. Many protein and nanoparticles 
conjugations have been attempted on methotrexate, but none showed a significant 
specificity towards cancer cells. In this work, we developed an innovative conjugate of 
methotrexate to annexin A5 with a satisfactory and stable loading drug ratio. The drug 
conjugate delivers a toxicity on triple negative breast cancer and lymphoma cell lines 
equivalent to the one of the free drugs. The ANXA5-MTX conjugate also turned out to 
not deliver any significant toxicity on the two tested human endothelial cell lines, making 











Animal model tests of the novel annexin A5-methotrexate conjugate should be conducted 
to evaluate its potential as a therapeutic. The slower blood clearance and the enhanced 
microvascular permeability give the conjugate a better pharmacokinetic profile for a 
higher and specific drug fraction delivered to the tumor site and lower off-target effects 
due to the lower diffusion of the conjugated drug in systemic tissues.   
A catalytic assay should be conducted to analyze the activity of the enzyme DHFR, a 
hallmark of the cellular toxicity of methotrexate, to allow for a more specific 
quantification of methotrexate toxicity in cells, and to support the Alamar Blue cell 
viability assays. A cellular uptake assay using a FITC linkage to ANXA5-MTX would 
allow for a quantification of the bound conjugate, that would reflect its binding efficacy, 
but also visualize the conjugate delivery in cells, its specific binding, and internalization 
with confocal microscopy. For the healthy cell viability assay, assessing the toxicity of 
the conjugate on human epithelial mammary healthy cells such as MCF-10A would 
confirm the specificity of the conjugate towards cancer cells. Evaluating the cytotoxicity 
of ANXA5-MTX conjugate on human breast cancer MCF-7 and MDA-MB 231 would 
show if the conjugate delivers a satisfactory toxicity on human cancer cells.  
Because the ANXA5-MTX conjugate would bind to the vasculature of tumors and 
therefore cut off the tumor’s blood supply, therapy in vivo should be combined with an 
mTOR inhibitor such as rapamycin, which inhibits the response of the tumor to hypoxia.  
Previous studies from our lab have shown that an enzyme prodrug targeted to the breast 
tumor vasculature using ANXA5 gave a significant reduction in the size of breast tumors 
in mice when rapamycin was added compared to when it was not added109. In addition, 
MTX causes an increase of reactive oxygen species (ROS) amount, which can lead to cell 
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necrosis and the release of tumor antigens110. Therefore, therapy in vivo should also be 
tested in combination with immune checkpoint inhibitors such as anti-CTLA-4, which 
we recently have shown to be effective in mice with breast tumors when combined with 
photothermal therapy of breast tumors that causes tumor antigens to be released (P. 
McKernan, N. Virani, G. Faria, C. Karch, R. Prada Silvy, D. Resasco, and R. Harrison, 
Targeted single-walled carbon nanotubes for photothermal therapy combined with 
immune checkpoint inhibition for the treatment of metastatic breast cancer, Nanoscale 



















ECM                   Extracellular matrix 
VEGF                 Vascular endothelial growth factor 
FGF                     Fibroblast growth factor 
TNBC                 Triple negative breast cancer 
MTX                   Methotrexate 
DHFR                 Dihydrofolate reductase 
FA                       Folic acid  
THF                    Tetrahydrofolate  
dAMP                 Deoxyadenosine monophosphate  
dGMP                 Deoxyguanosine monophosphate 
TS                       Thymidylate synthase  
[MTX]                Concentration of methotrexate 
[ANXA5]            Concentration of annexin A5 
ANXA5              Annexin A5 
ANXA5-MTX    Annexin-A5-methotrexate conjugate 
EDC                    Ethyldiethylcarbodiimid 
Sulfo-NHS          Sulfo-N-hydroxysuccinimid 
UV                      Ultraviolet  
SDS-PAGE         Sodium Dodecyl Sulfate – Polyacrylamide Gel Electrophoresis 
DMSO                Dimethyl sulfoxide 
DMF                   Dimethylformamide 
RPMI-1640         Rosewell Park Memorial Institute 
VCBM                Vascular cell basal medium 
DMEM                Dulbecco’s modified eagle medium 
FBS                     Fetal bovine serum 
HS                       Horse serum 
OD                      Optical density 
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IC50                    Inhibitory concentration at 50% 
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Initial ANXA5-MTX conjugation protocol (10 mg of conjugate)90,91 
1- Add 1,49 mg of methotrexate in 1,50 mL of PBS (3.29 x 10-3 mmol).  
2- Add 100 mg of EDC (5,21 x 10-1 mmol). 
The EDC will bind the carboxylic groups of methotrexate molecules to activate 
their reactivity with primary amines functions.  
3- Add 70 mg of sulfo-NHS (2,05 x 10-1 mmol).                                                                     
Sulfo-NHS stabilizes the EDC activated carboxylic groups, optimizing the 
efficiency of the methotrexate-annexin conjugation.  
4- Stir vigorously for 5 min. 
5- Add 2 µL of β-mercaptoethanol.                                                                                              
β-mercaptoethanol neutralizes the excess of EDC and NHS preventing their 
interference in downstream reactions. 
6- Immediately titrate the solution to a pH of 7.4. 
7- Add the methotrexate-sulfo-NHS solution dropwise to a 10 mL solution of 1 
mg/mL of annexin A5 (2,8 x 10-4 mmol). 
8- Stir gently for 12 hours. 
9- Centrifuge 10 min at 12 000 g. 
10- Retain the supernatant and discard the pellet. 
11- Dialyze against 2 L of PBS for 3 hours at 4°C.                                                                             
This step removes the rest of the unbound methotrexate as well as other upstream 
contaminants such as β-mercaptoethanol. 
12- Filter the supernatant with a 0.2 µm filter. 
13- Flash freeze the filtered conjugate solution then store it in -80°C liquid nitrogen.  
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Optimized ANXA5-MTX conjugation protocol (3.2 mg of conjugate) 
 
1- Dissolve 3 mg of methotrexate and 3 mg of EDC in 0.5 mL DMSO and protect 
the vial from light using foil.  
2- Place the solution in a 50°C water bath for 30 min. This step promotes the 
esterification of methotrexate by EDC. 
3- Cool the solution to room temperature and add it dropwise to a 2 mL PBS solution 
of 1.6 mg/mL of annexin A5 at a pH of 7.4. Make sure the solution is continuously 
stirred to promote the dissolution of the chemical reagents and titrate the pH of 
the solution before proceeding to the next step.  
4- Stir gently for 30 min at room temperature. At the end of this step, the solution 
should be clear and yellow.   
5- Dialyze the solution against 2L PBS pH 7.4 for 2 hours, change the media and 
redialyze for 2 hours. This step allows for the discard of undesired chemical 
reagents (NHS, EDC, free MTX).  
6- Retrieve the solution and centrifuge it at 3000 g for 5 min. The final solution 
should be yellow (at least slightly) and clear. If protein precipitates persist, 
recentrifuge the sample as priorly said. This step allows to eliminate the 
precipitated and cross-linked annexin A5 and the remaining free methotrexate.  
7- Filter the supernatant with a 0.2 µm filter. 






Alamar Blue assay protocol 
 
All steps from 1 to 8 are performed in sterile conditions. 
 
1. Prepare 15 mL of 40 000 cells/mL of media.  
2. Seed the central 60 wells (B2 – G11) of a 96 wells plate with 200 µL of the suspension 
containing 10 000 cells per well. Fill 3 wells with media without cells to establish the 
noise of the fluorescence. Fill the 30 outer wells of the plate with 200 µL of PBS to limit 
evaporation in the incubator.  
3. Let the plate incubate for 24 hours.   
4. When confluency has reached 70%, proceed to treatment: empty the wells with a 
multichannel pipette and refill them with 180 µL of fresh media.  
5. Add 20 µL of the appropriate treatment samples to the wells. The untreated and blank 
controls will be supplemented with 20 µL of PBS.  
6. Incubate cells for 48 hours.  
7. Carefully empty the wells of the plate using a multichannel pipette and refill them with 
200 µL of a priorly prepared solution of 10% Alamar Blue reagent in cell culture media.   
8. Incubate cells with Alamar Blue for 2-4 hours to allow dye uptake and reduction.   
9. Transfer the content of the plate to a black 96-well plate by using a multichannel pipette 
and by respecting the right order of wells. 
10. Read the fluorescence of the plate at 530 nm excitation and 590 nm emission and 
subtract the blank fluorescence value.  
